NCT07185308

Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer

Postbiotics Ameliorate Cancer Cachexia in Patients With Non-small-cell Lung Cancer: a Multicentre, Double-blind, Randomised Controlled Trial

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy of the oral postbiotic preparation JK-5G in improving body weight among patients with non-small-cell lung cancer (NSCLC)-related cachexia. By means of a randomized controlled trial, we will compare the between-group difference in body-weight changes between the JK-5G and placebo arms to clarify its nutritional therapeutic benefit.

Conditions

• Cachexia; Cancer

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Postbiotics, 2.5 g per dose, three times per day	Postbiotics oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).
DIETARY_SUPPLEMENT	Placebo, 2.5 g per dose, three times per day	Placebo made of cyclodextrine, oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).

Timeline

• Start date: 2025-11-01
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2025-09-22
• Last updated: 2025-09-25

Locations

1 site across 1 country: China